Biotage (BIOT) Q4 2024 earnings summary

Executive summary

• Full-year revenues reached SEK 2,056 million, up 10.5% year-over-year, surpassing SEK 2 billion for the first time, with recurring revenues at 72% and strong demand despite macroeconomic volatility.

• Q4 revenues were SEK 582 million, down 9.5% year-over-year due to a high prior-year base in Astrea, but core business showed sequential growth of 6%.

• Adjusted EBITDA for FY24 was SEK 547 million, up 6%; Q4 adjusted EBITDA was SEK 167 million.

• Strategic focus remains on expanding the customer base in clinical phase II, integrating Astrea for synergies, and reviewing the oligo business.

• Board proposes a dividend of SEK 1.65 per share for 2024, up from SEK 1.60.

Financial highlights

• FY net sales: SEK 2,056 million (up 10.5%); Q4 net sales: SEK 582 million (down 9.5%).

• FY adjusted EBITDA: SEK 547 million (26.6% margin); Q4: SEK 167 million (28.6% margin).

• FY operating profit: SEK 383 million (18.6% margin); Q4: SEK 175 million (30.0% margin).

• Adjusted cash from operations increased 33% year-over-year to SEK 579 million, representing 106% of adjusted EBITDA.

• Net cash at year-end: SEK 184 million; gross cash: SEK 434 million.

Outlook and guidance

• No full-year guidance provided; long-term revenue and profitability targets remain intact.

• 2025 focus on integrating Astrea, realizing synergies, and executing new leadership strategy.

• Astrea revenue expected to remain volatile in 2025 due to integration and customer concentration; oligo business under review.

• Cautious optimism for China in 2025 as business stabilizes.

• Focus on operational execution, cost structure streamlining, and market penetration in peptide purification.